ArticleFrontiers in oncology2021
High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Identification of Prognostic-Related Genes in Acute Myeloid Leukemia: A Study Based on TCGA Data Analysis.Biochemical genetics · 2026Article
- CLEC11A as a potential biomarker for prognosis and response to immunotherapy in colon adenocarcinoma.Discover oncology · 2025Article
- Identification and experimental validation of prognostic genes related to cytochrome c in breast cancer.Frontiers in genetics · 2025Article
- Machine learning-based biomarker screening for acute myeloid leukemia prognosis and therapy from diverse cell-death patterns.Scientific reports · 2024Article
- A machine learning model identifies M3-like subtype in AML based on PML/RARα targets.iScience · 2024Article
- CLEC11A expression as a prognostic biomarker in correlation to immune cells of gastric cancer.Biomolecules & biomedicine · 2024Article
- Identification and characterization of CLEC11A and its derived immune signature in gastric cancer.Frontiers in immunology · 2024Article
- Characterization of ligand-receptor pair in acute myeloid leukemia: a scoring model for prognosis, therapeutic response, and T cell dysfunction.Frontiers in oncology · 2024Article
- CLEC11A methylation is correlated to AML subtypes and cytogenetic risk factors but not patient demographics.PloS one · 2024Article
- Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity.Journal of clinical medicine · 2023Article
- CLEC11A improves insulin secretion and promotes cell proliferation in human beta-cells.Journal of molecular endocrinology · 2023Article
- The validation and clinical significance of LPCAT1 down-regulation in acute myeloid leukemia.Molecular biology reports · 2023Article
- Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myeloid leukemia (AML) is a heterogeneous disease of the hematopoietic system, for which identification of novel molecular markers is potentially important for clinical prognosis and is an urgent need for treatment optimization.
methodsWe selected C-type lectin domain family 11, member A (CLEC11A) for study
resultsMultiple public databases revealed that CLEC11A expression was higher in leukemia. The TCGA data revealed that high CLEC11A expression was linked with favorable prognosis (OS
conclusionCLEC11A may be used as a prognostic biomarker, and could do benefit for AML patients by providing precise treatment indications, and its unique gene pattern should aid in further understanding the heterogeneous AML mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.